Acquisition Upswing Leveraged by Indegene's acquisition in March 2024, Trilogy now sits within a larger life sciences commercialization platform, creating cross-sell opportunities for regulatory writing, medical communications, and end-to-end clinical documentation services across a broader client base.

Global Footprint Presence in three strategic regions (Germany, UK, US) enables multinational engagement with pharma and CROs, offering centralized or regionally tailored writing support and potential for expanded on-site or near-site teams to accelerate document turnaround times.

Scale with Quality With over 80 writers and a process geared toward reducing reviewer clarifications, there is a clear selling point for clients seeking faster regulatory approvals, improved study documentation quality, and more predictable timelines across clinical development programs.

Technology Enablement Adoption of standard collaboration and compliance tools (OneDrive, Microsoft Word, Google Suite, and compliance controls) supports seamless integration with client systems, enabling scalable, compliant, and audit-ready document production.

Growth Signals Revenue range indicates substantial scale; combined with Indegene’s ecosystem, Trilogy can pursue higher-value contracts, expand services into end-to-end regulatory writing and submission support, and win larger programs from mid-to-large pharma and CROs seeking integrated teams.